Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN3 | Q9UGI6 | 14/20 | 0.52 |
| ▸ | KCNN1 | Q92952 | 2/20 | 0.52 |
| ▸ | KCNN2 | Q9H2S1 | 2/20 | 0.52 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.48 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.41 |
| ▸ | CDK9 | P50750 | 3/20 | 0.41 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2028002 | 0.81 | MAPKAPK2 (0.43) | KCNN3CCNT1CDK9MAPKAPK2 | |
| SCHEMBL12587700 | 0.78 | PDE10A (0.43) | KCNN3KCNN1KCNN2PDE10ACCNT1 | |
| SCHEMBL20220569 | 0.74 | KCNN3 (0.56) | KCNN3KCNN1KCNN2PDE10ACCNT1 | |
| SCHEMBL5447969 | 0.73 | KCNN3 (0.66) | KCNN3KCNN1KCNN2PDE10ACDK9 | |
| SCHEMBL19512331 | 0.73 | KCNN3 (0.38) | KCNN3KCNN1KCNN2PDE10ACCNT1 | |
| SCHEMBL31668070 | 0.72 | CCNT1 (0.49) | CCNT1CDK9 | |
| SCHEMBL14158215 | 0.72 | KCNN3 (0.71) | KCNN3KCNN1KCNN2PDE10ACCNT1 | |
| SCHEMBL19526824 | 0.71 | KCNN3 (0.66) | KCNN3KCNN1KCNN2PDE10ACCNT1 | |
| SCHEMBL31668065 | 0.71 | PRKAB2 (0.45) | KCNN3KCNN1KCNN2PDE10ACCNT1 | |
| SCHEMBL31668093 | 0.71 | CCNT1 (0.47) | CCNT1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509602-B9 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | SENHWA BIOSCIENCES INC (TW) | 2017-11-01 | — | — | EP | disclosed |
| EP-2509602-B1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | SENHWA BIOSCIENCES INC (TW) | 2017-01-25 | — | — | EP | disclosed |
| US-9303033-B2 | Pyrazolopyrimidines and related heterocycles as CK2 inhibitors | SENHWA BIOSCIENCES, INC. (TW) | 2016-04-05 | — | — | US | disclosed |
| US-8575177-B2 | Pyrazolopyrimidines and related heterocycles as CK2 inhibitors | SENHWA BIOSCIENCES, INC. (TW) | 2013-11-05 | — | — | US | disclosed |
| US-20110152240-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152240-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | CDK2, CKS2, CSNK2A1 | KCNN3 2562/4885KCNN1 2748/4885KCNN2 2348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.